Joined October 2014
- Tweets 1,277
- Following 621
- Followers 184
- Likes 49
644 Photos and videos
21 Dec 2024
🎄 Season's Greetings from Medicilon! 🎉
#MerryChristmas #HappyNewYear #MedicilonUSA #BiotechInnovation #HolidayGreetings
32
17 Dec 2024
📷Medicilon Taiwan Workshop📷
📷New Approaches to Facilitate Drug Discovery and Development
📷 Learn More About Our Services: medicilon.com/services/
42
13 Dec 2024
Medicilon Supports Jemincare's JMX-2002 Liposome Injection Clinical Trial Approval
medicilon.com/cases/jmx-2002…
33
11 Dec 2024
🚀Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres
JM045 is a GnRH analog designed for prostate cancer.
Medicilon provided pharmacokinetic studies and GLP-compliant safety evaluations.
👇
medicilon.com/cases/jm045/
55
9 Dec 2024
HRS-9563, a cutting-edge siRNA Class I drug, has been approved for the treatment of hypertension.
Medicilon provided vital preclinical pharmacokinetics studies and GLP-compliant safety evaluations.
👇medicilon.com/cases/hengrui-…
37
4 Dec 2024
#PDXOs are 3D organoid models derived from PDX tumor tissues. At Medicilon, we have successfully developed nine PDXO models encompassing colorectal, pancreatic, gastric, leukemia, and prostate cancers. youtube.com/watch?v=vVUPXE6i…
203
22 Oct 2024
#Orthotopic tumor models aim to replicate the clinical setting of tumor growth and progression by implanting these cells or tissues at their anatomically correct or appropriate location within the body of an experimental animal. youtube.com/watch?v=T13A_gCc…
41
10 Oct 2024
Recently, Medicilon successfully passed the rigorous qualification review and assessment by the China National Accreditation Service for Conformity Assessment (#CNAS). medicilon.com/our-events/cmc…
37
10 Oct 2024
#Oligonucleotide drugs, as a new class of biomolecular therapeutics, demonstrate significant potential in gene expression regulation through precise targeting of #mRNA. medicilon.com/blog/featured-…
25
25 Sep 2024
FAQ – Efficient Strategies to Overcome Challenges in Preclinical Bioanalysis of XDC Drugs
medicilon.com/blog/featured-…
22
25 Sep 2024
After 20 years of accumulation, Medicilon boasts 260 evaluation models for non-tumor diseases, covering the inflammatory & immune diseases, CNS diseases, digestive diseases, , Metabolic diseases, cardiovascular diseases and other diseases.
medicilon.com/our-events/non…
16
25 Sep 2024
Recently, Medicilon officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai).
medicilon.com/our-events/gob…
27
25 Sep 2024
Medicilon leveraged its well-established pharmacokinetics research platform to provide early-stage animal pharmacokinetic services for Fuzerelisib.
medicilon.com/cases/genfleet…
65
25 Sep 2024
Value repeatedly verified! Medicilon congratulates its partner, EpimAb Biotherapeutics, on the overseas authorization of their BCMA×CD3 bispecific antibody EMB-06
medicilon.com/cases/epimab/
25
10 Sep 2024
High-Performance Liquid Chromatography (#HPLC) purification technology is a crucial purification technique in the biopharmaceutical industry, used to separate various components in a mixture based on their different chemical properties. medicilon.com/blog/featured-…
21
10 Sep 2024
Gas Chromatography-Mass Spectrometry (GC-MS) is a commonly used analytical technique that combines the methods of Gas Chromatography (#GC) and Mass Spectrometry (#MS). medicilon.com/blog/featured-…
19
10 Sep 2024
Recently, Suzhou Jingye Medicine & Chemical Co., Ltd. (Jingye) successfully obtained the "Approval Notice for the Market Launch of Chemical Raw Materials" (Notice No. 2024YS00864) issued by the #NMPA for its gadopentetate chemical raw material.#API #CMC
medicilon.com/cases/
42
20 Aug 2024
Syngeneic tumor models are highly effective in preclinical research for studying cancer biology, assessing therapeutic strategies, and understanding immune responses within a controlled genetic environment. #syngeneicmodels #tumormodels
medicilon.com/videos/syngene…
20
8 Aug 2024
Recently, Medicilon has successfully obtained an invention patent from the National Intellectual Property Administration for its self-developed project titled "Antibodies Targeting Nectin-4 and Their Various Applications"! #antibody
21